Computational Insights into the Interactions Between Calmodulin and the C/nSH2 Domains of P85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Jan 5

PMID 29300353

Citations 8

Authors

Duan Ni

Dingyu Liu

Jian Zhang

Shaoyong Lu

Affiliations

Soon will be listed here.

Abstract

Calmodulin (CaM) and phosphatidylinositide-3 kinase (PI3Kα) are well known for their multiple roles in a series of intracellular signaling pathways and in the progression of several human cancers. Crosstalk between CaM and PI3Kα has been an area of intensive research. Recent experiments have shown that in adenocarcinoma, K-Ras4B is involved in the CaM-PI3Kα crosstalk. Based on experimental results, we have recently put forward a hypothesis that the coordination of CaM and PI3Kα with K-Ras4B forms a CaM-PI3Kα-K-Ras4B ternary complex, which leads to the formation of pancreatic ductal adenocarcinoma. However, the mechanism for the CaM-PI3Kα crosstalk is unresolved. Based on molecular modeling and molecular dynamics simulations, here we explored the potential interactions between CaM and the c/nSH2 domains of p85α subunit of PI3Kα. We demonstrated that CaM can interact with the c/nSH2 domains and the interaction details were unraveled. Moreover, the possible modes for the CaM-cSH2 and CaM-nSH2 interactions were uncovered and we used them to construct a complete CaM-PI3Kα complex model. The structural model of CaM-PI3Kα interaction not only offers a support for our previous ternary complex hypothesis, but also is useful for drug design targeted at CaM-PI3Kα protein-protein interactions.

Citing Articles

Mechanistic insights into the role of calcium in the allosteric regulation of the calmodulin-regulated death-associated protein kinase.

Li X, Li B, Li J, Yang M, Bai Y, Chen K Front Mol Biosci. 2023; 9:1104942.

PMID: 36601586 PMC: 9806222. DOI: 10.3389/fmolb.2022.1104942.

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS.

Zhuang H, Fan J, Li M, Zhang H, Yang X, Lin L Front Oncol. 2022; 12:915512.

PMID: 36033504 PMC: 9399772. DOI: 10.3389/fonc.2022.915512.

Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect.

He X, Du K, Wang Y, Fan J, Li M, Ni D Front Mol Biosci. 2022; 9:860962.

PMID: 35463958 PMC: 9023742. DOI: 10.3389/fmolb.2022.860962.

Binding Selectivity of Inhibitors toward Bromodomains BAZ2A and BAZ2B Uncovered by Multiple Short Molecular Dynamics Simulations and MM-GBSA Calculations.

Wang L, Wang Y, Yang Z, Xu S, Li H ACS Omega. 2021; 6(18):12036-12049.

PMID: 34056358 PMC: 8154142. DOI: 10.1021/acsomega.1c00687.

Molecular Dynamics-Based Allosteric Prediction Method to Design Key Residues in Threonine Dehydrogenase for Amino-Acid Production.

Wu M, Sun Y, Zhu M, Zhu L, Lu J, Geng F ACS Omega. 2021; 6(16):10975-10983.

PMID: 34056250 PMC: 8153896. DOI: 10.1021/acsomega.1c00798.

References

Babu Y, Bugg C, Cook W . Structure of calmodulin refined at 2.2 A resolution. J Mol Biol. 1988; 204(1):191-204. DOI: 10.1016/0022-2836(88)90608-0. View

Tidow H, Nissen P . Structural diversity of calmodulin binding to its target sites. FEBS J. 2013; 280(21):5551-65. DOI: 10.1111/febs.12296. View

Lu S, Zhang J . Designed covalent allosteric modulators: an emerging paradigm in drug discovery. Drug Discov Today. 2016; 22(2):447-453. DOI: 10.1016/j.drudis.2016.11.013. View

Lu S, Li S, Zhang J . Harnessing allostery: a novel approach to drug discovery. Med Res Rev. 2014; 34(6):1242-85. DOI: 10.1002/med.21317. View

Duan Y, Wu C, Chowdhury S, Lee M, Xiong G, Zhang W . A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 2003; 24(16):1999-2012. DOI: 10.1002/jcc.10349. View

Prior I, Lewis P, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72(10):2457-67. PMC: 3354961. DOI: 10.1158/0008-5472.CAN-11-2612. View

Ogmen U, Keskin O, Aytuna A, Nussinov R, Gursoy A . PRISM: protein interactions by structural matching. Nucleic Acids Res. 2005; 33(Web Server issue):W331-6. PMC: 1160261. DOI: 10.1093/nar/gki585. View

Baspinar A, Cukuroglu E, Nussinov R, Keskin O, Gursoy A . PRISM: a web server and repository for prediction of protein-protein interactions and modeling their 3D complexes. Nucleic Acids Res. 2014; 42(Web Server issue):W285-9. PMC: 4086120. DOI: 10.1093/nar/gku397. View

Lu S, Jang H, Zhang J, Nussinov R . Inhibitors of Ras-SOS Interactions. ChemMedChem. 2015; 11(8):814-21. DOI: 10.1002/cmdc.201500481. View

10.

Cui C, Merritt R, Fu L, Pan Z . Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017; 7(1):3-17. PMC: 5237760. DOI: 10.1016/j.apsb.2016.11.001. View

11.

Bongiovanni D, Saccomani V, Piovan E . Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2017; 18(9). PMC: 5618553. DOI: 10.3390/ijms18091904. View

12.

Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S . PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer. 2009; 8:51. PMC: 2724395. DOI: 10.1186/1476-4598-8-51. View

13.

Siempelkamp B, Rathinaswamy M, Jenkins M, Burke J . Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas. J Biol Chem. 2017; 292(29):12256-12266. PMC: 5519374. DOI: 10.1074/jbc.M117.789263. View

14.

Vetter S, Leclerc E . Novel aspects of calmodulin target recognition and activation. Eur J Biochem. 2003; 270(3):404-14. DOI: 10.1046/j.1432-1033.2003.03414.x. View

15.

Nussinov R, Muratcioglu S, Tsai C, Jang H, Gursoy A, Keskin O . K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?. Expert Opin Ther Targets. 2016; 20(7):831-42. DOI: 10.1517/14728222.2016.1135131. View

16.

Pi J, Jiang J, Cai H, Yang F, Jin H, Yang P . GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. Drug Deliv. 2017; 24(1):1549-1564. PMC: 6920706. DOI: 10.1080/10717544.2017.1386729. View

17.

Wang M, Holderfield M, Galeas J, Delrosario R, To M, Balmain A . K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell. 2015; 163(5):1237-1251. DOI: 10.1016/j.cell.2015.10.041. View

18.

Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann H . Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol. 2005; 76(2):143-50. DOI: 10.1016/j.radonc.2005.06.024. View

19.

Weber T, Schaffhausen B, Liu Y, Gunther U . NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site. Biochemistry. 2000; 39(51):15860-9. DOI: 10.1021/bi001474d. View

20.

Nolte R, Eck M, Schlessinger J, Shoelson S, Harrison S . Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol. 1996; 3(4):364-74. DOI: 10.1038/nsb0496-364. View